Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Bifurcation in Blood Oscillatory Rhythms for Patients with Ischemic Stroke: A Small Scale Clinical Trial using Laser Doppler Flowmetry and Computational Modeling of Vasomotion.

Goltsov A, Anisimova AV, Zakharkina M, Krupatkin AI, Sidorov VV, Sokolovski SG, Rafailov E.

Front Physiol. 2017 Mar 23;8:160. doi: 10.3389/fphys.2017.00160. eCollection 2017.

2.

Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002.

Goltsov A, Tashkandi G, Langdon SP, Harrison DJ, Bown JL.

Eur J Pharm Sci. 2017 Jan 15;97:170-181. doi: 10.1016/j.ejps.2016.11.008. Epub 2016 Nov 8.

PMID:
27832967
3.

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.

Khalil HS, Langdon SP, Goltsov A, Soininen T, Harrison DJ, Bown J, Deeni YY.

Oncotarget. 2016 Nov 15;7(46):75874-75901. doi: 10.18632/oncotarget.12425.

4.

A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT.

Bown JL, Shovman M, Robertson P, Boiko A, Goltsov A, Mullen P, Harrison DJ.

Oncotarget. 2017 May 2;8(18):29657-29667. doi: 10.18632/oncotarget.8747.

5.

Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells.

Khalil HS, Goltsov A, Langdon SP, Harrison DJ, Bown J, Deeni Y.

J Biotechnol. 2015 May 20;202:12-30. doi: 10.1016/j.jbiotec.2014.09.027. Epub 2014 Nov 5.

PMID:
25449014
6.

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.

Goltsov A, Deeni Y, Khalil HS, Soininen T, Kyriakidis S, Hu H, Langdon SP, Harrison DJ, Bown J.

Cells. 2014 Jun 10;3(2):563-91. doi: 10.3390/cells3020563.

7.

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.

Goltsov A, Langdon SP, Goltsov G, Harrison DJ, Bown J.

Front Oncol. 2014 Feb 5;4:13. doi: 10.3389/fonc.2014.00013. eCollection 2014.

8.

SBSI: an extensible distributed software infrastructure for parameter estimation in systems biology.

Adams R, Clark A, Yamaguchi A, Hanlon N, Tsorman N, Ali S, Lebedeva G, Goltsov A, Sorokin A, Akman OE, Troein C, Millar AJ, Goryanin I, Gilmore S.

Bioinformatics. 2013 Mar 1;29(5):664-5. doi: 10.1093/bioinformatics/btt023. Epub 2013 Jan 17.

9.

Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, Faratian D.

Cell Signal. 2013 Jan;25(1):26-32. doi: 10.1016/j.cellsig.2012.09.014. Epub 2012 Sep 18.

PMID:
23000339
10.

Engineering simulations for cancer systems biology.

Bown J, Andrews PS, Deeni Y, Goltsov A, Idowu M, Polack FA, Sampson AT, Shovman M, Stepney S.

Curr Drug Targets. 2012 Nov;13(12):1560-74. Review.

PMID:
22974398
11.

Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.

Lebedeva G, Sorokin A, Faratian D, Mullen P, Goltsov A, Langdon SP, Harrison DJ, Goryanin I.

Eur J Pharm Sci. 2012 Jul 16;46(4):244-58. doi: 10.1016/j.ejps.2011.10.026. Epub 2011 Nov 9.

12.

Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.

Goltsov A, Faratian D, Langdon SP, Mullen P, Harrison DJ, Bown J.

Cell Signal. 2012 Feb;24(2):493-504. doi: 10.1016/j.cellsig.2011.09.030. Epub 2011 Oct 4.

PMID:
21996585
13.

Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.

Goltsov A, Faratian D, Langdon SP, Bown J, Goryanin I, Harrison DJ.

Cell Signal. 2011 Feb;23(2):407-16. doi: 10.1016/j.cellsig.2010.10.011. Epub 2010 Oct 14.

PMID:
20951800
14.

In Silico Screening of Nonsteroidal Anti-Inflammatory Drugs and Their Combined Action on Prostaglandin H Synthase-1.

Goltsov A, Lebedeva G, Humphery-Smith I, Goltsov G, Demin O, Goryanin I.

Pharmaceuticals (Basel). 2010 Jul 2;3(7):2059-2081.

15.

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P, Kay C, Um IH, Langdon S, Goryanin I, Harrison DJ.

Cancer Res. 2009 Aug 15;69(16):6713-20. doi: 10.1158/0008-5472.CAN-09-0777. Epub 2009 Jul 28.

16.

Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations.

Goltsov A, Maryashkin A, Swat M, Kosinsky Y, Humphery-Smith I, Demin O, Goryanin I, Lebedeva G.

Eur J Pharm Sci. 2009 Jan 31;36(1):122-36. doi: 10.1016/j.ejps.2008.10.015. Epub 2008 Nov 5.

PMID:
19028575

Supplemental Content

Loading ...
Support Center